Berlin Cures Welcomes Oliver von Stein as New CEO to Lead Next Phase of Innovation and Growth

Phase II study for BC 007 in the indication Long COVID to start in June BERLIN, June 15, 2023 /PRNewswire/ — Berlin Cures, a biotechnology company specialized in neutralizing functional autoantibodies (fAABs), is pleased to announce the appointment of its new Chief Executive Officer (CEO), Dr. Oliver von Stein. He assumes the role with immediate … Read more